UNICEF
3 United Nations Plaza, New York, NY, 10017, United States
Overview
UNICEF is the driving force that helps build a world where the rights of every child are realized. UNICEF has the global authority to influence decision-makers, and the variety of partners at grassroots level to turn the most innovative ideas into reality. That makes UNICEF unique among world organizations, and unique among those working with the young. UNICEF believes that nurturing and caring for children are the cornerstones of human progress. UNICEF was created with this purpose in mind – to work with others to overcome the obstacles that poverty, violence, disease and discrimination place in a child’s path. UNICEF believes that they can, together, advance the cause of humanity. UNICEF advocates for measures to give children the best start in life, because proper care at the youngest age forms the strongest foundation for a person’s future. UNICEF promotes girls’ education – ensuring that they complete primary education as a minimum – because it benefits all children, both girls and boys. Girls who are educated grow up to become better thinkers, better citizens, and better parents to their own children. UNICEF acts so that all children are immunized against common childhood diseases, and are well nourished, because it is wrong for a child to suffer or die from a preventable illness. UNICEF works to prevent the spread of HIV/AIDS among young people because it is right to keep them from harm and enable them to protect others. UNICEF helps children and families affected by HIV/AIDS to live their lives with dignity. UNICEF involves everyone in creating protective environments for children. UNICEF is present to relieve suffering during emergencies, and wherever children are threatened, because no child should be exposed to violence, abuse or exploitation. UNICEF upholds the Convention on the Rights of the Child. We work to assure equality for those who are discriminated against, girls and women in particular. UNICEF works for the Millennium Development Goals and for the progress promised in the United Nations Charter. UNICEF strives for peace and security. We work to hold everyone accountable to the promises made for children. UNICEF is part of the Global Movement for Children – a broad coalition dedicated to improving the life of every child. Through this movement, and events such as the United Nations Special Session on Children, we encourage young people to speak out and participate in the decisions that affect their lives. UNICEF is active in more than 190 countries and territories through country programmes and National Committees. UNICEF, the United Nations Children’s Fund.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Association
- Charity
- Child Care
- Non Profit
Investment portfolio
- Micron Biomedical
Participated · Series A · Nov 2022
Micron Biomedical develops a dissolvable microarray-based, needle-free platform for administration of drugs and vaccines. Its proprietary technology is designed to enable injection-free, painless and simple or self-administration, and to reduce or eliminate cold-chain requirements. The platform aims to enhance safety and efficacy while improving patient compliance. The company is led by CEO Steve Damon and is based in Atlanta, GA. Micron intends to use newly raised funds to expand operations and its R&D sector. Financially, the company extended its Series A to over $33M following the latest financing. Micron Biomedical is a clinical-stage life science company developing dissolvable microarray-based products for injection-free, painless administration of drugs and vaccines. Its core product is a microarray technology that reduces or eliminates cold chain requirements and enables community health workers to vaccinate quickly by applying a patch and pressing a button to confirm administration. Micron reported successful phase I/II clinical data in the Gambia across adults, toddlers, and infants as young as nine months using a leading commercial measles-rubella vaccine delivered via its microarray. The company plans to build a commercial-scale manufacturing facility—funded by a $23.6M Gates Foundation grant—to mass-produce needle-free vaccines and support larger clinical trials and regulatory approvals. Micron’s technology aims to expand vaccine access in low- and middle-income countries, improve patient acceptance in higher-income markets, and strengthen US national, veteran, and military health. Micron partners with the Bill & Melinda Gates Foundation, the CDC, PATH, and the Georgia Research Alliance and previously received a Gates grant in 2017 that enabled its first pediatric clinical trial. Micron Biomedical is an Atlanta-based life sciences company advancing dissolvable microarray-based drug and vaccine administration technology. Its patented microarray technology enables drugs and vaccines that today require cold storage and injection to be self-administered or caregiver-administered within minutes without refrigeration or a skilled health professional. The company aims to bring its dissolvable microarray products to markets globally. Micron has partnered with or received funding from private and public pharmaceutical and biotech companies as well as the Bill & Melinda Gates Foundation, the CDC, UNICEF, PATH and the Georgia Research Alliance. The company is led by CEO Steven Damon. The Series A extension will further support commercialization and global market efforts. Micron Biomedical is a clinical-stage life sciences company advancing its Micro Array Patch (MAP) technology to enable self-administration and less-skilled caregiver administration of drugs and vaccines without needles. Led by CEO Steven Damon and based in Atlanta, GA, the company’s pipeline includes vaccine and drug products partnered with pharmaceutical companies, foundations, and government agencies. Micron has demonstrated clinical efficacy for its MAP technology and since inception has supported R&D with more than $40 million in non-dilutive financing. The company intends to use the new funds to develop commercial manufacturing capacity, which is currently underway. Micron has received support and funding from foundations and public health organizations that have partnered on development and trials.
- EmiSwap
Participated · Seed · Jun 2021
EmiSwap is a community‑governed decentralized exchange (DEX) that offers high rewards for liquidity providers and 100% compensation for Ethereum transaction fees in $ESW governance tokens. The platform operates as a DAO in which $ESW holders vote on platform developments and participants are rewarded daily based on trade volume, with additional incentives such as limited‑edition NFT cards, bounty campaigns, and airdrops. EmiSwap received a grant from the NEAR Foundation to build on the NEAR Protocol and will deploy a cross‑chain AMM DEX to leverage NEAR’s sharded architecture for improved scalability. The integration aims to provide lightning‑fast transactions, enhanced security, interoperability, and higher staking yields, and to bring CEX‑style features like limit orders, frozen orders, and delayed executions to the DEX. Token economics include granting $ESW to holders and allocating 0.05% of daily trading commissions to them. The project notes standard KYC for launchpad participants and a restricted‑country list for token sales; EmiSwap is the first project in the EmiDAO alliance alongside several exchanges and partners. EmiSwap is the first community-governed decentralized exchange (DEX) in the EmiDAO ecosystem that combines liquidity incentives with gamified NFT mechanics. The platform advertises high returns for liquidity providers and a 100% refund of Ethereum gas fees paid in $ESW governance tokens. EmiSwap uses a scalable DAO model where $ESW token holders vote on development and participants are rewarded daily based on trade volume. The product roadmap includes utility "Magic Card" NFTs planned for Q3 2021 and a Card Wars tournament slated for Q4 2021, with NFTs usable in auctions and contests. EmiSwap also promotes cross-blockchain compatibility, multi-blockchain interoperability, and an advanced referral program. The project is presented as the first offering of the EmiDAO alliance, whose members are actively involved in product management and support.